|
Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer Clinical research trials and Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer. Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer clinical trial. Test subjects typically receive the most effective healthcare possible for their Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "O" Clinical Trials Conditions > Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer  Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
For Condition: Rectal Cancer,Anal Cancer,radiation enteritis,Drug Toxicity
Status: Recruiting
Sponsor(s): Radiation Therapy Oncology Group , National Cancer Institute (NCI)
Synopsis: RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. It is not yet known whether octreotide is effective in treating diarrhea. PURPOSE: Randomizedphase III trial to determine the effectiveness of octreotide in preventing or reducing diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer.
Details: OBJECTIVES: Primary - Determine the ability of octreotide to prevent the incidence of severe or life-threatening chemoradiotherapy-induced diarrhea (grades 3-4) in patients with anal or rectal cancer. Secondary - Compare the quality of life of patients treated with this drug vs placebo. - Compare the number of hospitalizations and use of antidiarrheal agents (e.g., Imodium®) related to diarrhea (or its complications) in patients treated with these drugs. - Compare treatment delays and/or dose reductions (chemotherapy and radiotherapy) in patients treated with these drugs. OUTLINE: This is a double-blind, placebo-controlled, randomized, multicenter study. Patients are stratified according to radiotherapy dose (< 50 Gy vs ≥ 50 Gy), chemotherapy dose (bolus vs continuous), and gender. Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive octreotide* intramuscularly (IM) 4-7 days before the start of chemoradiotherapy and on day 22 (± 3 days) during chemoradiotherapy. - Arm II: Patients receive placebo* IM 4-7 days before the start of chemoradiotherapy and on day 22 (± 3 days) during chemoradiotherapy. NOTE: *Patients receive a total of 2 injections of octreotide or placebo In both arms, treatment continues in the absence of unacceptable toxicity. Quality of life is assessed at baseline, at the completion of chemoradiotherapy, and at 3, 6, 9, and 15 months from the start of chemoradiotherapy. Patients are followed at 3, 6, 9, and 15 months from the start of chemoradiotherapy. PROJECTED ACCRUAL: A total of 226 patients (113 per treatment arm) will be accrued for this study within 2 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed primary anal or rectal cancer - No metastasis beyond the pelvic regional nodes - Must be scheduled to receive chemoradiotherapy PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Not specified Life expectancy - Not specified Hematopoietic - Not specified Hepatic - Liver function tests < 3 times upper limit of normal - No prior hepatic disease Renal - Not specified Gastrointestinal - No prior chronic or acute regional enteritis - No malabsorption syndrome - No prior inflammatory bowel disease that may exacerbate the radiotherapy toxicity - No grade 2 or greater uncontrollable diarrhea at baseline - No prior cholecystitis or gallstones, unless a cholecystectomy has been performed - No prior incontinence of stool Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - HIV negative - No uncontrolled diabetes (e.g., fasting glucose > 250 mg/dL) - No prior allergy or hypersensitivity to study drug or other related drug or compound - No other medical condition or mental impairment that would preclude study treatment and compliance PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - See Disease Characteristics - Prior chemotherapy allowed Endocrine therapy - At least 6 months since prior administration of any of the following: - Glucocorticoid therapy - Insulin sensitizers (e.g., metformin, pioglitazone, or rosiglitazone) - Exogenous growth hormone therapy Radiotherapy - See Disease Characteristics - No prior pelvic radiotherapy - No prior intensity-modulated radiotherapy - No concurrent radiotherapy for abdominal cancer - No concurrent hyperfractionated, split-course, or intensity-modulated radiotherapy - No brachytherapy prior to or after completion of all external beam radiotherapy Surgery - No prior abdominal-perineal resection or other surgical procedure leaving the patient without a functioning rectum - No colostomy Other - More than 30 days since other prior investigational drugs - No prior octreotide for cancer therapy-related diarrhea - No concurrent prophylactic antidiarrheal medication
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JafferAjani, , M.D. Anderson Cancer Center
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia *Recruiting*
Philadelphia, Pennsylvania, 19107-5541
United States
Recruiting Walter Curran 215-955-6700
H. Lee Moffitt Cancer Center and Research Institute *Recruiting*
Tampa, Florida, 33612-9497
United States
Recruiting Babu Zachariah 813-972-8424
University of Texas - MD Anderson Cancer Center *Recruiting*
Houston, Texas, 77030-4009
United States
Recruiting Jaffer Ajani 713-792-2828
Additional Information:
Study ID Numbers: CDR0000349441; RTOG-0315
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00075868
Other Rectal Cancer Studies:
1. Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
2. Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients with Primary Anal Cancer
3. Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer
4. SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
Related Studies:
Other Rectal Cancer Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
|
|
|
|
|
|
|
|
